Parkinson’s Disease psychosis is a common side-effect in Parkinson’s Disease patients, involving hallucinations and delusions (irrational beliefs). Roughly a half of people with Parkinson’s disease may show psychotic symptoms eventually. Recent research assessed safety and efficacy of a new antipsychotic drug called Pimavanserin, a selective serotonin 5-HT2A inverse agonist, which targets the serotonin system.
Pimavanserin is reported to be well tolerated, without significant safety concerns or worsening of motor function. Pimavanserin may benefit patients with Parkinson’s Disease psychosis. Further tests are underway, prior to this drug becoming available.
Drug may help Parkinson’s disease psychosis. London: NHS Choices; Behind the Headlines, November 4th 2013.
This relates to:
Full Text Link (Note: This article requires a suitable Athens password, a journal subscription or payment for access).
Cummings, J. Isaacson, S. [and] Mills, R. [et al] (2013). Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet, October 31st 2013, [Epub ahead of print]. (Click here to view the PubMed abstract).